Immix Biopharma, Inc. IMMX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.26M+102% | $16.26M+44.0% | $11.91M-8.5% | $11.77M+10.2% | $10.02M-6.1% | ||
| $15.81M+34.6% | $13.7M+20.3% | $12.14M+20.9% | $12.02M+26.3% | $11.75M+37.5% | ||
| $36.08M+65.7% | $29.96M+32.1% | $24.05M+4.3% | $23.78M+17.8% | $21.77M+13.3% | ||
| -$36.08M-65.7% | -$29.96M-32.1% | -$24.05M-4.3% | -$23.78M-17.8% | -$21.77M-13.3% | ||
| $1.12M+24.8% | $555.53K-45.4% | $524.67K-50.5% | $696.81K-29.6% | $899.67K+10.8% | ||
| -$34.95M-67.5% | -$29.4M-35.8% | -$23.53M-6.9% | -$23.09M-20.2% | -$20.87M-13.4% | ||
| —— | $37.72K-8.1% | $37.24K-2.9% | $40.67K+19.6% | $42.02K+39.7% | ||
| -$34.94M-67.2% | -$29.4M-36.0% | -$23.56M-7.6% | -$23.13M-21.6% | -$20.9M-14.8% | ||
| -$0.92-31.4% | -$0.89-15.6% | -$0.77+9.4% | -$0.77+8.3% | -$0.70+24.7% | ||
| -$35.78M-64.9% | -$29.71M-31.2% | -$23.84M-3.4% | -$23.66M-17.2% | -$21.7M-13.0% | ||
| -$36.08M-65.7% | -$29.96M-32.1% | -$24.05M-4.3% | -$23.78M-17.8% | -$21.77M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immix Biopharma, Inc. profitable?
- Immix Biopharma, Inc. is not currently profitable: it reported a net loss of $34.9M over the trailing twelve months.
- What is Immix Biopharma, Inc.'s earnings per share?
- Immix Biopharma, Inc.'s diluted EPS over the trailing twelve months is $-0.92.
- Where does Immix Biopharma, Inc.'s income statement data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.